SynAct Pharma AB (OSTO:SYNACT) Total Assets : kr213.35 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Total Assets?

SynAct Pharma AB's Total Assets for the quarter that ended in Mar. 2024 was kr213.35 Mil.

During the past 12 months, SynAct Pharma AB's average Total Assets Growth Rate was -33.40% per year. During the past 3 years, the average Total Assets Growth Rate was 186.50% per year. During the past 5 years, the average Total Assets Growth Rate was 69.30% per year.

During the past 8 years, SynAct Pharma AB's highest 3-Year average Total Assets Growth Rate was 186.50%. The lowest was 12.00%. And the median was 32.40%.

Total Assets is connected with ROA %. SynAct Pharma AB's annualized ROA % for the quarter that ended in Mar. 2024 was -45.14%. Total Assets is also linked to Revenue through Asset Turnover. SynAct Pharma AB's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

SynAct Pharma AB Total Assets Historical Data

The historical data trend for SynAct Pharma AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB Total Assets Chart

SynAct Pharma AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

25.91

21.59

38.37

142.60

228.02

SynAct Pharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															321.00	298.47	275.92	228.02	213.35

SynAct Pharma AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

SynAct Pharma AB's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	176.186	+	51.832
	=	228.02

SynAct Pharma AB's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	152.294	+	61.06
	=	213.35

SynAct Pharma AB (OSTO:SYNACT) Total Assets Explanation

Total Assets is connected with ROA %.

SynAct Pharma AB's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-99.624	/	( (228.018	+	213.354)	/ 2 )
	=	-99.624	/	220.686
	=	-45.14 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

SynAct Pharma AB's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (228.018	+	213.354)	/ 2 )
=	0	/	220.686
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

SynAct Pharma AB Total Assets Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

SynAct Pharma AB (OSTO:SYNACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

8F8:Germany

Address

Sheelevagen 2, Lund, SWE, 223 81

Website

https://www.synactpharma.se

SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines